Seven Fleet Capital Management LP bought a new position in Palisade Bio, Inc. (NASDAQ:PALI – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 327,500 shares of the company’s stock, valued at approximately $770,000. Seven Fleet Capital Management LP owned about 0.22% of Palisade Bio at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. XTX Topco Ltd raised its position in shares of Palisade Bio by 53.8% in the 4th quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock valued at $51,000 after acquiring an additional 7,584 shares during the period. Cetera Investment Advisers acquired a new position in Palisade Bio during the fourth quarter worth $25,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Palisade Bio during the 4th quarter worth about $26,000. Virtu Financial LLC acquired a new position in Palisade Bio during the fourth quarter valued at approximately $28,000. Finally, Atom Investors LP acquired a new stake in shares of Palisade Bio in the 4th quarter valued at approximately $33,000. 11.79% of the stock is owned by institutional investors.
Palisade Bio Trading Up 6.3%
NASDAQ PALI opened at $1.87 on Friday. The firm has a market capitalization of $324.59 million, a P/E ratio of -1.85 and a beta of 1.52. Palisade Bio, Inc. has a 12 month low of $0.53 and a 12 month high of $2.85. The business has a fifty day simple moving average of $1.97 and a 200 day simple moving average of $1.90.
Wall Street Analyst Weigh In
A number of equities analysts have commented on PALI shares. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Stifel Nicolaus assumed coverage on shares of Palisade Bio in a research note on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target on the stock. Wolfe Research began coverage on Palisade Bio in a research note on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price objective for the company. Weiss Ratings downgraded Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Finally, HC Wainwright initiated coverage on shares of Palisade Bio in a report on Thursday, March 26th. They set a “buy” rating and a $7.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.20.
View Our Latest Report on Palisade Bio
About Palisade Bio
Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.
The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.
Read More
- Five stocks we like better than Palisade Bio
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding PALI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palisade Bio, Inc. (NASDAQ:PALI – Free Report).
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
